Continued Access Increasingly Popular, Treatment IDEs Less Common – FDA
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers rarely invoke FDA's treatment-use option for investigational device exemptions, speakers agreed during the Food & Drug Law Institute's 48th annual conference in Washington, D.C